By Bill Berkrot (Reuters) - Regeneron Pharmaceuticals Chief Executive Len Schleifer on Monday ripped into Amgen Inc for its insistence on blocking sales of a rival Regeneron cholesterol drug while the appeals process in a patent infringement case plays out. A federal judge last week handed Regeneron and its partner Sanofi a stunning setback by banning sales of their LDL-lowering medicine Praluent, finding it infringed patents held by Amgen on its Repatha cholesterol drug. Regeneron and Sanofi were given 30 days before the ban takes effect to give them time to appeal. That was extended to 45 days on Monday. Speaking at the annual JP Morgan Healthcare Conference in San Francisco, Schleifer said Amgen had refused a request to delay any ban of Praluent sales until the appeal is heard, even though the judge in her ruling had said competition among the two drugs was in the public interest. "If they really cared about patients they wouldn't rip this drug from patients," the outspoken Schleifer said. "To say that you cannot wait, is that putting patients first? It's no small wonder that our industry isn't beloved," he continued. "If this industry is to survive, we have got to do the right thing by patients ... and still adequately reward our investors," Schleifer said. Earlier at the conference, Amgen CEO Robert Bradway reiterated that his company intended to defend its patents. He declined to say whether Amgen would consider a settlement in the case. Sanofi and Regeneron had no right to sell Praluent, Amgen said in an emailed statement. Amgen also said the companies were afforded a full and fair opportunity to challenge the validity of Amgen's patents at trial and the jury determined Amgen's patents to be valid. The expensive injectable drugs from both companies dramatically lower "bad" LDL cholesterol by blocking a protein called PCSK9. Both companies are expecting data this year that is likely to show that the drugs also cut the risk of heart attacks and deaths. Amgen's Bradway said he does not expect that data to be added to the Repatha label until 2018, and Amgen would not be allowed to promote those heart benefits until they are in the label. Without proof that the drugs prevent heart attacks, health insurers have been denying payment for three quarters of Repatha prescriptions written, Amgen said. The drug had just $40 million in third quarter sales. Amgen said if all Repatha prescriptions written had been filled it would be well on its way to being a $1 billion drug. Regeneron has run into similar resistance to Praluent with insurers refusing to pay for it. (Reporting by Bill Berkrot; Editing by Leslie Adler and Sunil Nair)
- Yahoo Sports
DEA agent who helped put Viktor Bout behind bars slams Brittney Griner swap: ‘We couldn’t even get two people for the world’s most notorious weapons trafficker’
Foreign policy experts warn the release of Viktor Bout could incentive future kidnappings of Americans.
- BuzzFeed News
Prince Harry Said The Royal Family Didn’t Think His Relationship With Meghan Markle Would Last Because She Was An Actor
“The fact that I was dating an American actress was probably what clouded their judgment more than anything else at the beginning.”View Entire Post ›
- Women's Health
Brie Larson is super sculpted from her abs to her legs in an orange bikini in new Instagram pics taken in a sauna. Brie opts for unconventional workouts.
- The Telegraph
Prince Harry appeared annoyed with his wife at one point in their new Netflix documentary when she joked about having to curtsey to the late Queen.
- NBC News
Former President Donald Trump declined Thursday to appeal a court order ending his lawsuit challenging the FBI’s seizure of documents from his Mar-a-Lago
- Rolling Stone
The GOP is condemning the president for securing the release of the WNBA star while former Marine Paul Whelan remains imprisoned in Russia
(Bloomberg) -- Every December, the Trump Organization would cut a check to a mail room employee. In a good year, the check was for $5,975. In less prosperous times, it was closer to $4,000. Most Read from BloombergTesla's Troubles Are Piling Up While Elon Musk Is Distracted With TwitterPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtWNBA Star Griner Freed in One-for-One Swap for Arms DealerPeru’s President A
- The Week
The rumored reason why AOC is facing a House ethics probe
Meghan Markle Says She Learned Reality of Royal Life After Hug with Kate Middleton and Prince William
"Like I was a hugger, always been a hugger," Meghan Markle said in the Netflix docuseries Harry & Meghan. "I didn't realize that that is really jarring for a lot of Brits"
- Kansas City Star
The 27-year-old didn’t show up to the Chicago hospital where she works, and friends grew concerned when they didn’t hear from her.
- Fox News
A mountain lion has been euthanized after it barged into a home in Sonoma County, California, and dragged out a woman's pet border collie by its neck last month.
- Business Insider
Liz Cheney resurfaced Paul Gosar's deleted tweet supporting Donald Trump's call to terminate the US Constitution: 'Time to condemn Trump yet?'
Donald Trump suggested the "termination" of rules and regulations in the Constitution that led to disputed voter fraud in the 2020 election.
And they've got strong feelings about her line of work.
Brittney Griner, the American basketball star imprisoned in Russia, was released on Thursday (Dec. 8) in a prisoner swap for Viktor Bout, a Russian arms dealer whose notoriety earned him the epithet “Merchant of Death.”
- NBC News
FedEx driver allegedly told investigators Texas girl was still alive after he struck her with vehicle
A FedEx driver panicked after striking a 7-year-old girl in Texas with his work van and threw her in the truck, where he killed her, authorities said.
Prince Harry’s Net Worth Reveals How Much He & Meghan Made For Their Netflix Doc—It’s in the 9 Figures
Plus, how much he inherited from Princess Diana and Queen Elizabeth.
- Kansas City Star
The fight between the teacher and student happened in the middle school classroom
- NBC Sports Boston
The Boston Red Sox' signing of Japanese outfielder Masataka Yoshida to a lucrative five-year contract had some MLB evaluators at a loss for words, per ESPN's Kiley McDaniel.
- Fighting Irish Wire
You gotta be bleepin' me.
- Lebron Wire
Warriors superstar Stephen Curry gave his all-time starting five - but it didn't include LeBron James.